4.2 Review

Advances in mass spectrometry-based cancer research and analysis: from cancer proteomics to clinical diagnostics

期刊

EXPERT REVIEW OF PROTEOMICS
卷 13, 期 6, 页码 593-607

出版社

TAYLOR & FRANCIS LTD
DOI: 10.1080/14789450.2016.1182431

关键词

Mass spectrometry; cancer research; cancer proteomics; clinical diagnostics; clinical mass spectrometry; mass spectrometry imaging; REIMS; MALDI; biotyping; pharmacokinetics

资金

  1. Waters Corporation
  2. National Institute for Health Research University College London Hospitals Biomedical Research Centre
  3. EPSRC
  4. MRC [G0301107] Funding Source: UKRI
  5. Engineering and Physical Sciences Research Council [1498422] Funding Source: researchfish

向作者/读者索取更多资源

Introduction: The last 20years have seen significant improvements in the analytical capabilities of biological mass spectrometry (MS). Studies using advanced MS have resulted in new insights into cell biology and the etiology of diseases as well as its use in clinical applications.Areas covered: This review discusses recent developments in MS-based technologies and their cancer-related applications with a focus on proteomics. It also discusses the issues around translating the research findings to the clinic and provides an outline of where the field is moving.Expert commentary: Proteomics has been problematic to adapt for the clinical setting. However, MS-based techniques continue to demonstrate potential in novel clinical uses beyond classical cancer proteomics.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.2
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据